RG
ICPT

Redmile Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Redmile Group’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,212
Closed -$524K – 61
2014
Q3 		$524K Buy
2,212
+1,150
+108% +$293K 0.06% 50
2014
Q2 		$251K Sell
1,062
-50,051
-98% -$13.2M 0.03% 45
2014
Q1 		$16.9M Sell
51,113
-214,836
-81% -$72.5M 2.01% 24
2013
Q4 		$18.2M Buy
+265,949
New +$15.4M 2.24% 20

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Redmile Group's ICPT Position: Q4 2014 in Review

Redmile Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2014, closing a stake of 2,212 shares — an estimated $524K sold.

Redmile Group first reported a position in ICPT in Q4 2013 and held it in 4 quarters. The position peaked at $18.2M in Q4 2013. 169 funds tracked by Wall St. Rank hold ICPT as of Q4 2014.

  • Redmile Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Redmile Group sold 2,212 Intercept Pharmaceuticals, Inc. shares in Q4 2014, an estimated $524K.
  • Redmile Group first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 4 quarters.
  • Redmile Group's Intercept Pharmaceuticals, Inc. position peaked at $18.2M in Q4 2013.
  • 169 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2014.

Based on Redmile Group's 13F filing for Q4 2014, filed 18 Feb 2015.